SPONSOR
Princess Maxima Center for Pediatric Oncology
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2
Conditions studied: NeuroblastomaAcute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryAcute Lymphoblastic Leukemia
Princess Maxima Center for Pediatric Oncology is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Neuroblastoma, Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Princess Maxima Center for Pediatric Oncology
How many clinical trials has Princess Maxima Center for Pediatric Oncology sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Princess Maxima Center for Pediatric Oncology, of which 3 are actively recruiting participants. These trials cover conditions including Neuroblastoma, Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Princess Maxima Center for Pediatric Oncology research focus on?
Princess Maxima Center for Pediatric Oncology clinical trials span Neuroblastoma, Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, and additional conditions. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Princess Maxima Center for Pediatric Oncology clinical trial?
To participate in a Princess Maxima Center for Pediatric Oncology trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Princess Maxima Center for Pediatric Oncology trials with current recruitment status updated daily.
Clinical Trials by Princess Maxima Center for Pediatric Oncology
NCT07399821 Phase 1, Phase 2
Recruiting
An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
Neuroblastoma
NCT05745714 Phase 1, Phase 2
Recruiting
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic Leukemia, in Relapse
NCT05751044 Phase 1, Phase 2
Recruiting
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic Leukemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology